Pyoderma gangrenosum: A systematic review

Giornale Italiano di Dermatologia e Venereologia

Volumn 149, Issue 5, 2014, Pages 587-600

  Cozzani, E ^a   Gasparini, G ^a   Parodi, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Inflammatory bowel diseases; Pyoderma gangrenosum; Therapeutics

Indexed keywords

BIOLOGICAL PRODUCT; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

CHILDHOOD; CLINICAL FEATURE; CYTAPHERESIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FAMILIAL DISEASE; HUMAN; LOCAL THERAPY; MEDICAL LITERATURE; PATHOGENESIS; PREGNANCY; PROGNOSIS; PUSTULE; PYODERMA GANGRENOSUM; REVIEW; SYSTEMIC THERAPY; ARTHRITIS; COMPLICATION; DISEASE PREDISPOSITION; FEMALE; INFLAMMATORY BOWEL DISEASE; LEUKAPHERESIS; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOLOGY; PREGNANCY COMPLICATION; SKIN ULCER;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; LYMPHOPROLIFERATIVE DISORDERS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; PYODERMA GANGRENOSUM; SKIN ULCER; THALIDOMIDE;

EID: 84925559305     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008-17.
2. Brocq L. Nouvelle contribution a l'étude du phagédeénisme géométrique. Ann Dermatol Syphiligr 1916.
3. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma ecthyma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph 1930;22:655-80.
4. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. London: Mosby; 2003.
5. Jackson JM, Elston DM. Pyoderma Gangrenosum. Medscape 2012 [Internet]. Available at: http://www.emedicine.medscape.com/article/1123821-overview#a0101 [cited 2013, Apr 2].
6. Yu GV, Brarens RM, Meszaros A. Atypical pyoderma gangrenosum of the lower extremity: a case presentation and comprehensive disease overview. Available at http://www.podiatryinstitute.com/pdfs/Update-2004/2004-12.pdf [cited 2013, Feb 16].
7. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181-4.
8. Wollina U. Pyoderma gangrenosum a review. Orphanet J Rare Dis 2007;2:19.
9. Fulbright RK, Wolf JE, Tschen JA. Pyoderma Gangrenosum at surgery sites. J Dermatol Surg Oncol 1985; 11:883-6.
10. Freedberg IM, Eisen A, Wolff K, Austen K, Goldsmith L, Katz S, editors. Fistzpatrick's dermatology in general medicine. 6th edition. New York: McGraw-Hill; 2003.
11. Von der Driesch P. Pyoderma gangrenosum a report of 44 cases with follow-up. Br J Dermatol 1997;137:1000-5.
12. Fosse CE, Clark AR, Inabienet R, Camacho F, Jorizzo JL. An open-lable pilot study of alefacept for the traetment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008;22:943-9.
13. Lorincz M, Kleszky M, Szaloki T JR, Szaloki T. Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis. Orv Hetil 2010;151:144-7.
14. Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3rd et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998;111:259-68.
15. Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF 3rd, Petty HR. Aberrantintegrin (CR4; alpha(x)beta2; CDllc/CD18) oscillations on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol 1998;111:154-8.
16. Marzano AV, Cugno M, Trevisan V, Lazzari R, Fanoni D, Berti E, Crosti C. Inflammatory cells, cytokines and matrix metalloprotei-nases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int J Immunopathol Pharmacol 2011;24:451-60.
17. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000;80:595-604.
18. Shpiro D, Gilat D, Fisher-Feld L, Shemer A, Gold I, Trau H. Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor. Br J Dermatol 1998;138:368-9.
19. Shore RN. Pyoderma gangrenosum, defective neutrophil Chemotaxis and leukemia. Arch Dermatol 1976;1792-3.
20. Su WPD, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum J Cutan Pathol 1986;13:323-30.
21. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33:787-802.
22. James WD, Berger TG, Elston DM. Andrews' diseases of the skin. Clinical dermatology. 11th edition. Philadelphia, PA: Saunders Elsevier; 2011.
23. Gungor K, Gonen S, Kisakol G, Dikbas O, Kaya A. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest 2006;29:575-6. I
24. White LE, Villa MT, Petronic-Rosic V, Jiang J, Medenica MM. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed 2006;5:96-8.
25. Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to ge-fitinib (Iressa): revealing sycosis-and pyoderma gangrenosum-like lesions. Int J Dermatol 2006;45:1002-3.
26. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996, 34:395-409.
27. Bonamigo RR, Olm GS, Razera F. Neutrophilic deramtoses: Part I. An Bras Dermatol 2011;86:195-209.
28. Miller J, Yentzer BA, Clark A, Jorizzo JL, Fieman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62:646-54.
29. Cainelli T, Giannetti A, Rebora A. Manuale di dermatologia medica e chirurgica. 4th edition. Milan: McGraw-Hill; 2008.
30. Dockery GL. Cutaneous Disorders of the lower extremities. Phila-pelphia: WB Saunders; 1997.
31. Schwaegerle SM, Bergfeld WF, Senitzer D, Tidrick RT. Pyoderma gangrenosum: a review. J Am Acad Dermatol 1988;18:559-68.
32. Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 1972;106:901-5.
33. Koester G, Tarnower A, Levisohn D, Burgdorf W. Bullous pyoderma gangrenosum. J Am Acad Dermatol 1993;29:875-8.
34. O'Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 1978;114:1061-4.
35. Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma: 27 a localized vegetative form of pyoderma gangrenosum. J AmAcad Dermatol 1988;18:511-21.
36. Gibson LE, Daoud MS, Muller SA, Perry HO. Malignant pyodermas revisited. Mayo Clin Proc 1997;72:734-6.
37. Ho SA, Tan WP, Tan AW, Wong SN, Chua SH. Scrotal pyoderma gangrenosum associated with Crohn's disease. Singapore Med J 2009;50:397-400.
38. Kim TH, Oh SY, Myung SC. Pyoderma gangreno sum of the penis. J Korean med Sci 2009;24:1200-02.
39. Ecra E, Ahogo KC, Sangaré A, Kaloga M, Kassi K, Kouamé K et al. [An uncommon localization of pyoderma gangrenosum on thepenis of an HIV infected patient in the Ivory Coast]. Bull Soc Pathol Exot 2009;102:85-7.
40. Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol 2000;43:108-12.
41. Muster AJ, Bharati S, Herman JJ, Esterly NB, Gonzales-Crussi F, Holbrook KA. Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. J Pediatr 1983;102:243-8.
42. Marie I, Levesque H, Joly P, Reumont G, Courville P, Baudrimont M et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol 2001;44:137-9.
43. Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin Dermatol 2000;18:339-47.
44. Vadillo M, Jucgla A, Podzamczer D, Rufi G, Domingo A. Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol 1999; 141:541-3.
45. Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis-an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999;40:331-4.
46. Yoshida C, Kojima H, Ishigaki T, Katsura Y, Kaneko S, Suzukawa K et al. Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7) (q10;q10). Eur J Haematol 2004;72:149-53.
47. Nurre LD, Rabalais GP, Callen JP. Neutrophilic dermatosis associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Pediatr Dermatol 1999;16:214-6.
48. Lyon CC, Smith AJ, Griffiths CE, Beck MH. The spectrum of skin disorders in abdominal stoma patients. Br J Dermatol 2000;143:1248-60.
49. Funayama Y, Kumagai E, Takahashi K, Fukushima K, Sasaki I. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum 2009;52:311-4.
50. Wollina U, Haroske G. Pyoderma Gangrenosum. Current opinion in Rheumatology 2011;23:50-6.
51. Thornton JR, Teague RH, Lon-Beer TS, Read AE. Pyoderma gangrenosum and ulcerative colitis. Gut 1979;21:247-8.
52. Callen JP. Pyoderma gangrenosum. Lancet 1998;351:581-5.
53. Marzano AV, Menicanti C, Crosti C, Trevisan V. Neutrophilic dermatoses and inflammatory bowel diseases. G Ital Dermatol Venereol 2013;148:185-96.
54. Marzano VA, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoimflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet's syndrome: a comprehensive review and disease classification criteria. Springer 2013 [Internet]. Available at http://link.springer.com/artic110.1007/s12016-012-8351-x/fulltext.html#Sec1 [cited 2013, Feb 14].
55. Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L et al. Auto-inflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012;12:22-30.
56. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997;72:611-5.
57. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S et al. Mutations in CD2BP1 disrupt binding PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Gen 2002;11:961-9.
58. Dinarello CA. A clinical perspective of IL-lbeta as the gatekeeper of inflammation. Eur J Immunology 2011;41:1203-17.
59. Wierzbicka-Hainaut E, Le Naoures H, Bonneric-Malthieu F, Debiais P, Levillain P, Pierre F et al. [Recurring pyoderma gangrenosum in pregnancy]. Ann Dermatol Venereol 2010;137:225-9.
60. Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J MEd 1985;55:173-86.
61. Malone JC, Slone SP, Wills-Frank LA, Fearneyhough PK, Lear SC, Goldsmith LJ et al. Vascular inflammation (vasculitis) in sweet syndrome: aclinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol 2002;138:345-9.
62. Farina MC, Requena L, Dòmine M, Soriano ML, Estevez L, Barat A. Histopathology of cutaneous reaction to granulocyte colony-stimulating factor: anotherpseudomalignancy. J Cutan Pathol 1998;25:559-62.
63. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). Dermatol Ther 2011;24:273-84.
64. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002;341:1412-8.
65. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004;43:790-800.
66. Yang CC, Hsieh FS, Lee JY. Pyoderma gangrenosum complicated with ecthyma gangrenosum. Br J Dermatol 2004;150:1025-6.
67. Feliciani C, De Simone C, Amerio P. Dermatological sings during inflammatory bowel diseases. Eur Rev Med Pharmacol Sci 2009;13:15-21.
68. Fonder MA, Lazarus GS, Cowan DA, Ronson-Cook B, Kohli AR, Mamelak AJ. Treating the chronic wound: a practical approach to the care of non-healing wounds and wound care dressings. J Am Acad Dermatol 2008;58:185-206.
69. Russell B. Phagedenic and gangrenous ulceration of the skin complicating ulcerative colitis. (Phagedena Geometricum). Br J Dermatol 1950;62:114-24.
70. Nybaek H, Olsen AG, Karlsmark T, Jemec GB. Topical therapy for peristomal pyoderma gangrenosum. J Cutan Med Surg 2004; 8:220-3.
71. Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005;32:199-203.
72. Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD.Topical tracrolimus [FK506] in the treatment of recalcitrant parasternal pyoderma gangrenosum associated with Crohn's disease: report of two cases. Colorectal Dis 2004;6:250-3.
73. Pitarch G, Torrijos A, Mahiques L, Sanchez-Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol 2006;86:64-5.
74. Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther 2012;25:158-72.
75. Sanders CJ, Hulsmans RF. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993;51:262-4.
76. Bellini V, Simonetti S, Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2008;22:113-5.
77. Wolf R, Ruocco V. Nicotine for pyoderma gangrenosum. Arch Dermatol 1998;134:1071-2.
78. Langenbach N, Goetz A, Hohenleutner U, Landthaler M. Effectiveness of 4% disodium cromoglycate in treatment of disseminated pyoderma gangrenosum. Acta Derm Venereol 1996;76:501-2.
79. Tsele E, Yu RC, Chu AC. Pyoderma gangrenosum response to topical nitrose mustar. Clin Exp Dermatl 1992;17:437-40.
80. Nguyen LQ, Weiner J. Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis 1997;19:842-4.
81. Braun-Falco M, Stock K, Ping J, Hein R. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum. Br J Dermatol 2002;147:829-31.
82. Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn's disease and its mucocutaneous involvement. Skinmed 2007;6:179-85.
83. Hafner J, Kühne A, Trüeb RM: Successful grafting with EpiDex in pyoderma gangrenosum. Dermatology 2006, 212:258-9.
84. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol 2000;14:187-90.
85. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controller by adding minocycline and sulphasalazine to the regimen. Cutis 1996;57:315-9.
86. Daniels NH, Callen JP. Mycophenolate mofetil i san effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 2004;140:1427-9.
87. Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996;57:326-8.
88. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for reclcitrant pyoderma gangrenosu. J Am Acad Dermatol 1996;5:720-4.
89. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clinic Proc 2000;75:842-4.
90. Kontochristopoulos GJ, Savropoulos PG, Gregoriou S, Zakopou-lou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology 2004;209:233-6.
91. Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologie disorders. Dermatol Clin 2000;18:459-73.
92. Von der Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137:1000-5.
93. Binua AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165:1244-50.
94. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000;60:273-92.
95. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controller trial. Gut 2006;55:505-9.
96. Gisondi P, Girolomoni G. Impact of TNF-oc antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol 2013;148:243-8.
97. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 2006;54:128-234.
98. Jacob SE, Weisman RS, Kerdel FA. Pyoderma Gangrenosum-rebel without a cure? Int Dermatol 2008;47:192-4.
99. Woodson J. Use of efalizumab for successful treatment of chronic recalcitrant pyoderma gangrenosum. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7 2006; San Francisco, CA.
100. Foss CE, Clark AR, Inabinet R, Camacho F, Jorizzo JL. An open-lable pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008;22:943-9.
101. Ikeda K, Hamada T, Otsuka M, iwatsuki K. beneficial effects of neutrophilic-targeted therapy for pyoderma gangrenosum associated with ulcertive colitis. Eur J Dermatol 2011; 21:804-5.
102. Hanai H, Takeda Y, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leukocyta-pheresis in patient with inflammatory bowel disease: a concise review. Clin Exp Immuol 2011;163:50-8.